INCY
NASDAQIncyte Corp.
SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological Resarch
Price$102.33+3.50 (+3.54%)
2026-03-042026-06-05
News · 26 weeks92-28%
2025-12-142026-06-07
Mix5190d
- Other20(39%)
- Insider18(35%)
- SEC Filings7(14%)
- Analyst2(4%)
- Leadership2(4%)
- Earnings2(4%)
Latest news
25 items- PRMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva ("FOP") will be presented at ENDO 2026, the Endocrine Society's annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604863826/en/
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J covered exercise/tax liability with 25,469 shares, decreasing direct ownership by 10% to 240,848 units (SEC Form 4) to cover taxes4 - INCYTE CORP (0000879169) (Issuer)
- PRIncyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCLThe Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed across prespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes The frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide adde
- INSIDERPrincipal Accounting Officer Tray Thomas sold $199,665 worth of shares (2,051 units at $97.35), decreasing direct ownership by 9% to 21,132 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Bienaime Jean Jacques exercised 15,000 shares at a strike of $84.53 and covered exercise/tax liability with 13,059 shares, increasing direct ownership by 9% to 22,782 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- SECSEC Form DEFA14A filed by Incyte Corp.DEFA14A - INCYTE CORP (0000879169) (Filer)
- PRIncyte to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Invest
- ANALYSTBernstein initiated coverage on Incyte with a new price targetBernstein initiated coverage of Incyte with a rating of Mkt Perform and set a new price target of $99.00
- INSIDERDirector Clancy Paul J exercised 15,000 shares at a strike of $84.53 and sold $1,423,950 worth of shares (15,000 units at $94.93) (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERAmendment: CMO & Head of Late-Stage Dev. Stein Steven H was granted 44,124 shares, increasing direct ownership by 129% to 78,327 units (SEC Form 4)4/A - INCYTE CORP (0000879169) (Issuer)
- INSIDERAmendment: President, Global Head of R&D Cagnoni Pablo J was granted 31,517 shares, increasing direct ownership by 13% to 266,317 units (SEC Form 4)4/A - INCYTE CORP (0000879169) (Issuer)
- PRIncyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug DiscoveryThe expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data Incyte data will be securely used to train Genesis' next-generation GEMS AI platform as part of Incyte's efforts to speed up drug development across multiple programs Genesis to receive $120M with potential for success-based milestone payments and royalties Incyte (NASDAQ:INCY) and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expa
- PRIncyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and DevelopmentIncyte (NASDAQ:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison's AI scientist, for Incyte's discovery and development work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519992433/en/ Kosmos will be embedded across the Incyte discovery and development lifecycle, enabling continuous learning from translational and clinical data, real-time synthesis of evidence and predictive models of therapeutic performance. The initial deployment will be focused on high-impact use cases in target discovery and validation and translational biology, centered on embedding Edison's AI capabilitie
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Incyte Corp.SCHEDULE 13G/A - INCYTE CORP (0000879169) (Subject)
- PRIncyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 CongressData from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts Session Oral and poster presentations to feature new data for INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with myeloproliferative neoplasms (MPNs) Incyte (NASDAQ:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. "The breadth of the data that will be showcased at the 2026 EHA Congress high
- INSIDERDirector Baker Bros. Advisors Lp exercised 30,000 shares at a strike of $84.53 (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- PRIncyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic DermatitisFirst presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) at the 2026 EADV Symposium The vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator's Global Assessment Treatment Success) Data support Type-II variation application sub
- INSIDEREVP & Chief Financial Officer Upadhyay Suketu was granted 26,343 shares (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERSEC Form 3 filed by new insider Upadhyay Suketu3 - INCYTE CORP (0000879169) (Issuer)
- PRIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Incyte Corporation (NASDAQ:INCY) announced today that it granted equity inducement awards to Suketu (Suky) Upadhyay, the Company's new Executive Vice President and Chief Financial Officer, pursuant to the Company's 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company's Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). As an inducement material to his employment, Mr. Upadhyay received, with a grant and vesting commencement date of May 4, 2026, an award of stock options to purchase 38,429 shares of the Company's common stock, an a
- PRNew First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2]Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval by the US FDA[3]Australian-led research played key role in the development of NIKTIMVO, a first-in-class novel colony stimulating factor-1 receptor (CSF-1R) blocking antibody.[1],[4]SINGAPORE, May 3, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administrati
- PRIncyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host DiseaseJakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi® (ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi Jakafi XR will be available for pharmacy orders by May 8 Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versu
- PRIncyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of May: BofA Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 1:40 pm (PDT) and RBC 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 10:30 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generati
- SECSEC Form DEFA14A filed by Incyte Corp.DEFA14A - INCYTE CORP (0000879169) (Filer)
- SECSEC Form DEF 14A filed by Incyte Corp.DEF 14A - INCYTE CORP (0000879169) (Filer)
INCY FAQ
6 questionsWhat does Incyte Corp. do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial...Where does INCY stock trade?
Incyte Corp. (INCY) is listed on NASDAQ.What sector and industry is INCY in?
Incyte Corp. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.What are analysts saying about INCY?
Incyte Corp. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Mkt Perform on 2026-05-22.What companies are similar to INCY?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc), SYNH (Syneos Health Inc.). Compare INCY side-by-side with any of them on Quantisnow.How can I track INCY on Quantisnow?
Quantisnow aggregates Incyte Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INCY to receive live email and push alerts on every new disclosure.